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Denise V. D’Angelo, M.P.H.,a Nedra Whitehead, Ph.D., M.S.,b Kristen Helms, M.S.P.H.,c
Wanda Barfield, M.D., M.P.H.,a and Indu B. Ahluwalia, M.P.H., Ph.D.a
a Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease
Control and Prevention, Atlanta, Georgia; b RTI International, Research Triangle Park, North Carolina; and c Science
Applications International Corporation, San Diego, California
Objective: To study birth outcomes among live born infants conceived by women who used infertility treatment.
Design: Population-based surveillance of women who recently delivered a live infant.
Setting: The birth outcomes among infants whose mothers used assisted reproductive technology (ART) or ovu-
lation stimulation medications alone were compared with the outcomes of infants conceived without treatment.
Patient(s): Stratified random sample of women who were attempting conception and gave birth to a live infant in
six US states (n ¼ 16,748).
Intervention(s): Assisted reproductive technology and ovulation stimulation.
Main Outcome Measure(s): Adjusted odds ratios for perinatal outcomes.
Result(s): The prevalence of infertility treatment use overall among women attempting conception was 10.9%
(5.4% ART procedures, 5.5% ovulation stimulation medications). Singletons of mothers who received ART
procedures were more likely to be born with low birthweight, preterm, and small for gestational age (SGA) than
singleton infants conceived without treatment. Singleton infants of mothers who used ovulation stimulation
medications alone were more likely to be SGA than singleton infants conceived without treatment. No differences
were found between ART and no treatment twin infants.
Conclusion(s): Among singleton infants, ART is associated with decreased fetal growth, decreased gestational
length, and SGA; ovulation stimulation alone is associated with SGA. (Fertil Steril 2011;96:314–20. 2011
by American Society for Reproductive Medicine.)
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Use of infertility treatments, such as assisted reproductive technol-
ogy (ART) procedures and ovulation stimulation medications with-
out ART, has increased dramatically in the United States. Assisted
reproductive technology includes treatments in which both the oo-
cyte and the sperm are handled in the laboratory. Medications to
stimulate ovulation are used in ART procedures before retrieval of
oocyte; however, these medications can also be used for non-ART
treatments. From 1997–2000, the annual number of ART infants
born increased by 44% (1). In 2006, about 1% of all US births
were to women who had undergone ART procedures (2). Assisted
reproductive technology use has been associated with an elevated
risk of pregnancy complications for the mother and adverse out-
comes for the infant, with the most common complication being
multiple gestation (1–6). According to data from the US ART
Surveillance System, 49% of 2006 ART births were multiple
gestation births compared with only 3% multiple gestation for all
US births (2, 7). Infants born as multiples have an increased risk
of preterm delivery, low birthweight, infant mortality, and long-
term disability (8–10).
In addition to problems associated with multiple gestation deliv-
eries, studies have found that singleton ART-conceived infants are
more likely to be low birthweight compared with singletons whose
mothers did not use ART (11–14). Some studies have also found
a greater risk of birth defects among singletons and multiples
conceived using ART compared with those conceived without
treatment (15–18); however, the evidence is inconsistent and
suggests that risk may be related to underlying infertility (19–21).
Concern about long-term sequelae of ART use, such as neurodeve-
lopmental problems, has been identified as an area needing further
research (22–25).
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TABLE 1
Prevalence of selected characteristics by infertility treatment status, six PRAMS states, 2000–2003.
Characteristic
ART (n[ 920) Medication only (n[ 904) No treatment (n[ 14,673)
% 95% CI % 95% CI % 95% CI
Pluralitya
Singleton 75.5 71.5, 79.5 93.4 91.7, 95.1 98.8 98.6, 99.0
Twin 22.1 18.2, 26.0 5.9 4.3, 7.5 1.2 1.0, 1.4
Triplet 2.4 1.6, 3.2 0.7 0.3, 1.1 0.0 0.01,0.03
Maternal characteristics
Agea
<25 y 2.4 0.8, 4.0 11.2 8.1, 14.3 22.5 21.5, 23.5
25–34 y 56.2 51.0, 61.4 68.2 63.6, 72.7 62.6 61.5, 63.8
R35 y 41.4 36.2, 46.6 20.6 16.8, 24.5 14.8 14.1, 15.6
Racea
White 88.5 85.1, 91.9 90.3 87.4, 93.3 85.5 84.7, 86.4
Black 6.5 3.8, 9.1 4.4 2.5, 6.3 8.9 8.2, 9.6
Other 5.0 2.8, 7.3 5.3 2.9, 7.6 5.6 5.0, 6.1
Ethnicitya
Non-Hispanic 94.9 92.5, 97.4 90.2 87.1, 93.4 84.7 83.8, 85.7
Hispanic 5.1 2.6, 7.5 9.8 6.6, 12.9 15.3 14.3, 16.2
Marital statusa
Married 94.7 92.3, 97.1 92.0 89.1, 94.9 84.3 83.4, 85.2
Other 5.3 2.9, 7.7 8.0 5.1, 10.9 15.7 14.8, 16.6
Educationa
<12 y 2.8 1.0, 4.6 6.8 3.9, 9.6 13.3 12.4, 14.1
12 y 15.6 11.6, 19.6 20.2 16.3, 24.1 24.4 23.4, 25.5
>12 y 81.6 77.3, 85.9 73.1 68.6, 77.5 62.3 61.1, 63.5
Paritya
Primiparous 53.8 48.5, 59.1 51.3 46.3, 56.2 40.1 38.9, 41.2
R1 child 46.2 40.9, 51.5 48.7 43.8, 53.7 59.9 58.8, 61.1
Incomea
<Median 21.2 16.0, 26.3 29.3 23.7, 34.8 44.7 43.2, 46.1
RMedian 78.8 73.7, 84.0 70.8 65.2, 76.3 55.3 53.9, 56.8
Birth interval
%6 mo 3.0 0.8, 5.2 2.7 0.9, 4.5 2.9 2.4, 3.3
>6 to <24 mo 26.5 20.7, 32.2 28.0 22.6, 33.4 30.6 29.3, 31.9
R24 mo 70.6 64.7, 76.5 69.3 63.8, 74.8 66.5 65.2, 67.9
Multivitamin use before pregnancya
R4 times/wk 81.0 76.8, 85.2 70.1 65.7, 74.5 48.0 46.8, 49.2
0–3 times/wk 19.0 14.8, 23.2 29.9 25.5, 34.3 52.0 50.8, 53.2
Cigarette smoking last trimester of pregnancya
No 96.8 95.0, 98.6 97.3 95.8, 98.7 91.3 90.6, 92.0
Yes 3.2 1.4, 5.0 2.7 1.3, 4.2 8.7 8.0, 9.4
Alcohol consumption last trimester of pregnancy
No 91.0 87.7, 94.3 94.2 91.9, 96.6 94.0 93.4, 94.5
Yes 9.0 5.7, 12.3 5.8 3.4, 8.1 6.0 5.5, 6.6
Body mass indexa
Underweight (<19.8) 10.9 7.6, 14.2 9.6 6.7, 12.4 12.3 11.5, 13.1
Normal (19.8–26) 57.1 51.7, 62.4 51.5 46.4, 56.5 55.2 54.0, 56.4
Overweight (26–29) 9.1 6.3, 11.9 12.5 9.1, 15.9 12.9 12.1, 13.7
Obese (>29) 22.9 18.3, 27.6 26.5 22.1, 30.9 19.6 18.6, 20.5
Infant outcomes
Birthweighta
R2,500 g 77.9 74.9, 80.8 89.4 87.7, 91.0 94.3 94.1, 94.5
1,500–2,499 g 17.2 14.7, 19.8 8.6 7.1, 10.0 4.6 4.3, 4.8
<1,500 g 4.9 3.7, 6.1 2.1 1.4, 2.7 1.1 1.0, 1.3
Gestational agea
R37 wk 69.9 65.5, 74.3 85.0 82.3, 87.8 91.4 90.8, 91.9
<37 wk 30.1 25.7, 34.5 15.0 12.2, 17.7 8.6 8.1, 9.2
SGAa,b
No 85.5 82.0, 89.0 88.9 85.9, 91.8 93.3 92.7, 93.8
Yes 14.5 11.0, 18.0 11.1 8.2, 14.1 6.7 6.2, 7.3
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Although research has been focused on the laboratory component
of ART, the effect of ovulation stimulation medications alone has
been less well studied. Birth outcomes among infants of mothers
who used ovulation stimulation medications without ART is an im-
portant group to consider given that a recent study estimated that
4.6% of US infants born in 2005 were conceived as a result of non-
ART ovulation stimulation (26). In addition, there is some evidence
that superovulation can affect DNAmethylation, causing imprinting
changes, which can effect fetal growth and development (27).
The purpose of this study was to examine infant outcomes among
women who reported using either ART or ovulation stimulation
medications without around the time of conception using a large
population-based sample. We used data from the Pregnancy Risk
Assessment Monitoring System (PRAMS), which allowed us to
investigate and control for multiple maternal characteristics,
behaviors, and lifestyle factors, as well as differentiate ART and
ovulation stimulation outcomes.
MATERIALS AND METHODS
PRAMS is a population-based surveillance system of maternal and infant
health indicators funded in part by the Centers for Disease Control and Pre-
vention and administered by state health departments. The unit of analysis for
PRAMS is the woman who delivered a live birth. Mothers of twins and trip-
lets are sampled once, and these women report on the health of one of their
infants who is randomly selected at the time of sampling. The PRAMS does
not sample women who give birth to multiples beyond triplets. The data are
weighted for sample design, nonresponse, and noncoverage to represent all
women who delivered a live birth in each participating PRAMS state for
each calendar year. Details on the PRAMSmethodology have been published
previously (28), and are available from the PRAMS web site http://
www.cdc.gov/prams. The Centers for Disease Control and Prevention Insti-
tutional Review Board approved the PRAMS protocol and all participating
states approved the study plan.
We analyzed data from six states (Alabama, Illinois, Maine, Maryland,
Nebraska, and Oklahoma) selected because they were the only PRAMS states
to collect data on the use of both ART and ovulation stimulation medications
from 2000–2003.We used 2000–2003 data for this analysis because these spe-
cific infertility measures were only available on the PRAMS survey during
those years.Overall weighted response rates for each statewere 70%orgreater
for each year of data. In the PRAMSquestionnaire structure, only womenwho
reported they were trying to become pregnant answered the questions on in-
fertility treatment use. Therefore, our analysis was restricted to women who
were attempting a pregnancy. In the absence of other fertility-related variables
in the dataset (such as time to pregnancy), this subgroup of women constituted
an appropriate population to study differences between birth outcomes of
women who used infertility treatments and those who did not.
The PRAMS dataset included variables linked from the birth certificate
(1989 standard birth certificate) and variables from the questionnaire. We ob-
tained information on maternal age, race, ethnicity, education level, marital
status, parity, plurality, infant gestational age, birthweight, and other medical
risk factors (identified by a dichotomous indicator) from the birth certificate.
We used PRAMS questionnaire data on maternal prepregnancy height and
weight, multivitamin use, and smoking and alcohol consumption during
the third trimester of pregnancy. The dependent variable in the analysis
was birth outcome (birthweight, gestational age, small for gestational age
(SGA), length of infant hospital stay after birth, admission to the neonatal in-
tensive care unit (NICU), and infant death (between the time of the live birth
and survey response). One percent or less of the data for the outcome
variables was missing, with the exception of birthweight (<4%). SUDAAN
softwarewas used for the analysis to account for PRAMS’ complex sampling
design and statistical weighting (29). More detail on the study methods can
be found in Supplemental Table 1.
There were 35,848 respondents in the dataset representing 1,351,718
women who delivered a live infant in six states during 2000–2003; 16,748 re-
ported theywere trying to get pregnant with their new baby andwere included
in the analysis. There were 251 women (1.5%) with missing information on
use of infertility treatment who were excluded from the analysis. Among the
remaining 16,497 women, 15,406 gave birth to singleton infants, 980 to
twins, and 111 to triplets. We did not examine differences in birth outcomes
among triplet infants separately because of small numbers; however, mothers
of triplet infants are included in the prevalence estimates in Table 1.
RESULTS
Overall, 1,824 (10.9%) women whowere trying to become pregnant
reported using infertility treatment. There were 920 (5.5%) women
who reported using ART, 904 (5.4%) women who reported use of
ovulation stimulation medications alone, and 14,673 (87.6%)
women who reported no infertility treatment.
There were significant differences by infertility treatment status
for the following maternal characteristics: age, race, ethnicity, mar-
ital status, education, parity, income, multivitamin use before
TABLE 1
Continued.
Characteristic
ART (n[ 920) Medication only (n[ 904) No treatment (n[ 14,673)
% 95% CI % 95% CI % 95% CI
Hospital staya
<5 days 77.4 73.5, 81.2 87.5 84.9, 90.1 91.3 90.6, 91.9
R5 days 22.6 18.8, 26.5 12.5 9.9, 15.1 8.7 8.1, 9.4
NICUa
No 77.1 73.2, 81.1 85.2 82.1, 88.3 89.8 89.1, 90.4
Yes 22.9 18.9, 26.8 14.8 11.7, 17.9 10.2 9.6, 10.9
Infant deatha
No 98.8 98.1, 99.4 99.6 99.4, 99.9 99.4 99.3, 99.6
Yes 1.2 0.6, 1.9 0.4 0.1, 0.6 0.6 0.4, 0.7
Note: SGA ¼ small for gestational age; NICU ¼ neonatal intensive care unit; ART ¼ assisted reproductive technology; CI ¼ confidence interval; PRAMS ¼
Pregnancy Risk Assessment Monitoring System.
a Characteristic is significantly different between treatment groups (c2 test, P< .05).
b SGA was calculated accounting for infant race, sex, gestational age, and birthweight among black and white infants. Infants with missing data on any of
these items or with race designated as ‘‘other’’ were excluded.
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pregnancy, cigarette smoking in the last trimester of pregnancy, and
prepregnancy body mass index (BMI). There were no differences in
alcohol consumption during pregnancy or birth interval (among
multiparous women) (Table 1).
Infant Outcomes
The prevalence of adverse infant outcomes increased with the use of
more intensive treatment.Women using ARTwere at the highest risk
and those not using any treatment were at the lowest risk. This pat-
tern is evident not only in the overall sample (Table 1), but alsowhen
restricted to singleton infants (Table 2). Among singleton infants,
there was a significant difference in the prevalence of low birth-
weight (very low birthweight and low birthweight combined was
9.8% of the ART group, 6.5% for the medication-only group, and
5.1% for the no treatment group). Preterm birth (<37 weeks gesta-
tion) was also highest among the ART group (16.1%), followed by
the medication-only group (11.0%), and lowest in the no treatment
group (8.0%). The pattern is similar for SGA, infant hospital stay
longer than 5 days, and infant spending time in the NICU, although
long hospital stay and NICU admission were not statistically
significant (Table 2). All of the affected infants in the study had
more than one study outcome.
Among mothers of singleton infants, those who used ART were
more than twice as likely to have a low birthweight infant (crude
odds ratio [cOR]: 2.10, confidence interval [CI]: 1.58, 2.79) as
women who did not undergo any treatment. Mothers who used
ART were almost two times more likely to give birth before 37
weeks gestation (cOR: 1.94, CI: 1.42, 2.65) and more likely to
have an SGA infant (cOR: 1.72, CI: 1.13, 2.61). Their infants
were also significantly more likely to spend 5 or more days in the
hospital (cOR: 1.49, CI: 1.04, 2.14), and more likely to be admitted
to the NICU (cOR: 1.53, CI: 1.12, 2.24). There was no significant
difference in very low birthweight or infant death (Table 3).
In the adjusted analysis, we looked among singletons only at
outcomes that were significant in the unadjusted analysis described
previously. Women who used ART were more than two times as
likely to have a low birthweight singleton infant (adjusted OR
[AOR]: 2.20, CI: 1.55, 3.13). ART use was also associated with pre-
term birth (AOR: 1.91, CI 1.31, 2.80) and delivering an SGA infant
(AOR: 1.98, CI: 1.21, 3.24) (Table 3). For hospital stay of 5 days or
more, therewere interactions with parity, age, and BMI. Further anal-
ysis showed no significant association for primiparous women. Only
the relationship among multiparous young women with low or nor-
mal BMI was significant; however, the estimate is imprecise (AOR:
9.30, CI: 3.18, 27.19) (Table 4). For admission to theNICU,we found
interactions with parity and age. Again, there was no association
for primiparous women. However, for multiparous young women,
we found an association between ART use and NICU admission
with an imprecise estimate (AOR: 7.16, CI: 3.23, 15.87) (Table 4).
Comparing mothers of singleton infants who used ovulation
stimulation medications without ART to women who received no
treatment, those who used ovulation stimulation medications alone
were significantly more likely to have an SGA infant (cOR: 1.59,
CI: 1.11, 2.27) than women who received no treatment. In the ad-
justed analysis, this association remained significant (AOR: 1.71,
CI: 1.09, 2.69) (Table 3).
Among twin births, there were no significant differences in any of
the infant outcomes that we examined when comparing ART users
with women who received no treatment. Nor did we find any
TABLE 2
Prevalence of birth outcomes among singletons by infertility treatment status, six PRAMS states, 2000–2003.
Infant outcome
ART Medication only No treatment
% 95% CI % 95% CI % 95% CI
Birthweighta
R2,500 g 90.2 88.0, 92.4 93.5 92.2, 94.8 94.9 94.7, 95.1
1,500, 2,499 g 8.0 6.0, 10.0 5.2 4.1, 6.3 4.1 3.9, 4.3
<1,500 g 1.8 1.0, 2.6 1.3 0.8, 1.9 1.0 0.9, 1.1
Gestational agea
R37 wk 83.9 79.7, 88.1 89.0 86.4, 91.6 92.0 91.5, 92.5
<37 wk 16.1 11.9, 20.3 11.0 8.4, 13.6 8.0 7.5, 8.6
SGAa,b
No 89.3 85.4, 93.2 90.0 86.9, 93.1 93.5 93.0, 94.0
Yes 10.7 6.8, 14.6 10.0 6.9, 13.1 6.5 6.0, 7.0
Hospital stay
<5 d 88.0 84.3, 91.7 90.1 87.5, 92.7 91.6 91.0, 92.2
R5 d 12.0 8.3, 15.7 9.9 7.3, 12.5 8.4 7.8, 9.0
NICU
No 85.3 80.9, 89.5 87.4 84.2, 90.6 90.2 89.5, 90.9
Yes 14.7 10.5, 19.1 12.6 9.4, 15.8 9.8 9.2, 10.6
Infant death
No 99.6 99.2, 100.0 99.7 99.5, 99.9 99.5 99.4, 99.6
Yes 0.4 0, 0.8 0.3 0.1, 0.54 0.5 0.4, 0.6
Note: SGA ¼ small for gestational age; NICU ¼ neonatal intensive care unit; ART ¼ assisted reproductive technology; CI ¼ confidence interval; PRAMS ¼
Pregnancy Risk Assessment Monitoring System.
a Characteristic is significantly different between treatment groups (c2, P< .05).
b SGA was calculated accounting for infant race, sex, gestational age, and birthweight among black and white infants. Infants with missing data on any of
these items or with race designated as ‘‘other’’ were excluded.
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significant differences in twin outcomes comparing women who
used ovulation stimulation medications without ART with women
who received no treatment. However, many of the effect sizes
were large among the medication-only group, possibly indicating
a relationship, but inconclusive due to the small sample size (data
not shown).
DISCUSSION
Overall, 10.9% of the women in our study used infertility treatment.
This is higher than other reports because our study was restricted to
women who were trying to become pregnant, rather than the entire
birth population (2). We confirmed the previously reported relation-
ship that singleton infants born to mothers who undergo ART proce-
dures are more likely to be low birthweight (11–15), preterm (13, 14,
30), or SGA (13, 30, 31) than singleton infants born to mothers who
did not undergo treatment.We further provide one of a few studies of
this size and diversity showing an association between the use of
ovulation stimulation medications without ART and infants being
born small for gestational age for singleton infants. Although the
literature on twin outcomes is inconsistent, our study using a large
population-based sample corroborates the findings of a number of
studies that do not note any difference among outcomes of twin in-
fants born after ART compared with spontaneously conceived twins
(11, 30, 32). Our findings relative to ovulation stimulation-only
twins were inconclusive.
Our findings suggest a relationship between ART use and the
risk of an infant’s hospital stay of 5 or more day and NICU admis-
sion for multiparous women less than 35 years of age. Other stud-
ies have found increased NICU admission for singleton ART
births, and longer hospitalizations for ART infants (33, 34, 36),
but not specific to younger women. There is some evidence that
increased maternal morbidity and infant low birthweight linked
with ART use may be associated with poor gamete quality, or
other factors related to the maternal or paternal subfertility
rather than the ART procedures. The research in this area is
inconclusive and the exact mechanism responsible for the
difference in infant outcomes has not been identified (13, 21, 35,
37, 38). Although the confidence intervals around our estimates
for these indicators are wide, the findings may suggest that the
cause of underlying infertility is playing a role in the increased
use of hospital services among some ART singleton infants.
These younger, multiparous women may be more likely to have
an underlying cause of infertility that could affect fetal growth or
development.
We found that mothers who reported using ovulation stimula-
tion medications without ART were more likely to have an in-
fant that was small for gestational age compared with infants
who were conceived without treatment. Other studies have
also linked ovulation stimulation with adverse infant outcomes
such as prematurity and low birthweight, but not specifically
SGA (35, 36).
TABLE 3
Association between use of ART or ovulation stimulation medications and infant outcomes among singleton infants, six PRAMS
states, 2000–2003.
Infant outcome
ART Medication only
cOR 95% CI AORa 95% CI cOR 95% CI AORb 95% CI
Birthweight
R2,500 g Ref Ref Ref Ref
1,500–2,499 g 2.10 1.58, 2.79 2.20 1.55, 3.13 1.26 0.99, 1.62 — —
<1,500 g 1.41 0.95, 2.10 — — 1.27 0.81, 1.97 — —
Gestational age
R37 wk Ref Ref Ref Ref
<37 wk 1.94 1.42, 2.65 1.91 1.31, 2.80 1.23 0.95, 1.63 — —
SGAb
No Ref Ref Ref Ref
Yes 1.72 1.13, 2.61 1.98 1.21, 3.24 1.59 1.11, 2.27 1.71 1.09, 2.69
Hospital stay
<5 d Ref Ref Ref
R5 d 1.49 1.04, 2.14 c c 1.20 0.89, 1.63 — —
NICU
No Ref Ref Ref
Yes 1.53 1.12, 2.24 d d 1.32 0.98, 1.78 — —
Infant death
No Ref Ref Ref
Yes 0.81 0.34, 1.90 — — 0.56 0.25, 1.23 — —
Note: cOR¼ crude odds ratio; SGA¼ small for gestational age; ART¼ assisted reproductive technology; CI¼ confidence interval; PRAMS¼Pregnancy Risk
Assessment Monitoring System.
a Adjusted odds ratio: adjusted for age, race, ethnicity, marital status, income, smoking, alcohol use, education, parity, prepregnancy bodymass index, state
of residence, medical risk factors.
b SGA was calculated accounting for infant race, sex, gestational age, and birthweight among black and white infants. Infants with missing data on any of
these items or with race designated as ‘‘other’’ were excluded.
c Interaction with parity, age, and body mass index, see Table 4.
d Interaction with parity and age, see Table 4.
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There are several limitations to this study. Although we con-
trolled for state of residence in our regression analysis, the data
are from six states selected based on their use of the PRAMS ques-
tions on infertility, and findings are not generalizable to other states
or the entire United States. The PRAMS data on use of ARTand ovu-
lation stimulation medications are self reported in the postpartum
period. A validation study by Schieve et al in 2006 (39) found that
using the infertility questions from 2000–2003, PRAMS overesti-
mates the number of ART births when compared with estimates
from the US ART Surveillance System suggesting that women
might be reporting past use of treatments. We do not have informa-
tion on the treatment used, on the underlying cause of infertility, or
on other potentially confounding factors such as gamete quality.
And, although the questions refer to the most recent pregnancy,
we do not know whether the procedures or medications directly
resulted in the pregnancy with the infant about whom the woman
is being surveyed.
Despite these limitations, PRAMS provides a large population-
based sample that enables examination of multiple infant out-
comes, and an appropriate comparison group of other women
who reported they were actively trying to get pregnant, which is
more similar to those women who use ART than the population
of all women delivering a live birth. The availability of multiple
covariates from the PRAMS survey allows for the use of robust
approaches to identify and control for possible confounding
variables.
The use of infertility treatments has become increasingly
common in the United States, and risks go beyond multifetal
pregnancies. The findings from this study add to the growing
body of literature on the use of infertility treatments and the
safety of these treatments for the infants that are conceived. Con-
sidering the elevated risks, especially for singleton births from
ART and ovulation stimulation medications alone, couples who
are considering treatment should be counseled on potential risks
to their singleton infants, in addition to the increased risk of hav-
ing a multiple birth as the result of ART or ovulation stimulation
medications.
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SUPPLEMENTAL MATERIAL
SUPPLEMENTAL TABLE 1
PRAMS methodology and indicators.
PRAMS methodology
In each state that conducts PRAMS, a stratified random sample of women who recently gave birth to a live infant is drawn from state birth
certificate records 2–6 months after birth. Data are collected by mailed questionnaire and nonrespondents are followed up by
telephone. The data areweighted for sample design, nonresponse, and noncoverage to represent all womenwho delivered a live birth in
each participating PRAMS state for the calendar year. Mothers of multiples are eligible to be sampled only once for their delivery.
Assessment of infant—the experiences for these women is based on the outcomes of one of their infants who is randomly selected at
the time of sampling. The randomization for twins is as follows: if the birth date lies between the first and fifteenth of the month, the first-
born twin is sampled; otherwise the second-born twin is sampled.
PRAMS infertility treatment indicators (2000–2003)
‘‘Did you take any fertility drugs to help you get pregnant with your new baby? (Fertility drugs include Clomid, Serophene, Pergonal,
or any other drugs that you may have taken to help you get pregnant.)’’
No
Yes
‘‘Did you use any medical procedures (assisted reproductive technology [ART]) to help you get pregnant with your new baby?
(Assisted reproductive technology [ART] procedures include IVF, GIFT, zygote intrafallopian transfer [ZIFT], ET, and donor oocytes.)’’
No
Yes
A woman was considered to have used ovulation stimulation medications if she answered ‘‘yes’’ to the first question and ‘‘no’’ to the
second question. A woman was considered to have used assisted reproductive technology (ART) if she answered ‘‘yes’’ to both
questions. Women who answered ‘‘yes’’ only to the second question were included in the ART group.
Definition of Birth Outcomes
Small for gestational age (SGA): SGA was calculated using an algorithm that accounted for infant race, sex, gestational age, and
birthweight among black and white infants. Infants with missing data on any of these items or with race designated as ‘‘other’’ were
excluded from the SGA analysis.
Birthweight: Birthweight was separated into three categories, normal birth weight (R2,500 g), low birthweight (1,500–2,499 g), and very
low birthweight (<1,500 g).
Gestational age: Gestational age was determined from the date of the last menstrual period (LMP) and clinical gestational age from the
birth certificate, using the algorithmdescribed by Alexander et al. (1). If gestational age could not be determined by LMPor clinical week,
we calculated it from the infant’s date of birth and the due date from the questionnaire. Recordswith incompatible infant birthweight and
gestational age, based on the criteria used by Adams et al. (2), were excluded. We defined preterm birth as gestational age<37 weeks.
Body mass index (BMI): BMI was calculated using 1990 Institute of Medicine categories based on self-reported prepregnancy height and
weight from the questionnaire (3).
Definition of covariates
Medical risk:Medical risk was identified by a dichotomous indicator on the birth certificate if themother had any one of 16 possible chronic
or pregnancy-induced conditions such as anemia, eclampsia, or hypertension (4).
Statistical methods
Bivariate analysis:We examined the characteristics of women who used ART, ovulation stimulation medications alone, and those who did
not use infertility treatments by calculation of percentages and 95% confidence intervals. We tested for differences between the
characteristics of these groups using c2 tests (significance defined as P< .05).
Multivariate analysis
Unadjusted analysis: We examined the unadjusted relationship between infant health outcomes and infertility treatments by calculating
crude odds ratios with 95% confidence intervals.
Adjusted analysis:We further examined health outcomes that were significantly associated with infertility treatment in the crude analysis
using logistic regression to adjust for other factors related to the birth outcomes. We then used a hierarchical modeling reduction
process to eliminate variables that neither interacted with nor confounded the relationship of interest. We eliminated variables from the
model that did not interact with or confound the relationship between infertility treatment and infant health outcomes. We identified
significant interactions using the likelihood ratio test. We defined a confounding variable as one that changed the estimate of the
relationship of the infertility treatment and health outcomes by 10% or more.
Covariates:We used a theory-driven process of choosing covariates based on their previously identified association with birth outcomes.
We examined age, parity, prepregnancy BMI, and presence of a medical risk factor for interactions with infertility treatment. We
examined state of residence, maternal age, race, ethnicity, marital status, income, smoking during pregnancy, drinking during
pregnancy, maternal education, parity, BMI, and medical risk factor as potential confounders.
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